

Correction: The increasing incidence of stage IV cervical cancer in the USA: what factors are related?

Francoeur AA, Liao C, Caesar MA, *et al.* The increasing incidence of stage IV cervical cancer in the USA: what factors are related? *Int J Gynecol Cancer* 2022; 32: 1115–1122. DOI: 10.1136/ijgc-2022-003728.

We have realized an unintentional error in our table for our submission to the *International Journal of Gynecologic Cancer*. The old table data for Tables 1, S3, S4, and S5 were mistakenly imported into the manuscript during the revision phase of the corrections. It does not change the focus of the paper or the results in the text. All other parts of the paper including the abstract, text, and figures are correct and based off of these tables. Tables 2, 3, S1, and S2 are not affected by this. The supplementary material has been replaced and please find the correct [table 1](#) below.

Table 1 Age adjusted incidence and trends of distant stage cervical cancer, Squamous cell carcinoma (SCC), and adenocarcinoma from 2001 to 2018 using USCS database

| | AAI 2001–2018 | | | AAI 2001–2018 | | | AAI 2001–2018 | |
|--------------------------------|---------------|-----------------------|--------------------|---------------|----------------------|--------------------------------|---------------|----------------------|
| | 2001 to 2018 | AAPC (95% CI) | | 2001 to 2018 | AAPC (95% CI) | | 2001 to 2018 | AAPC (95% CI) |
| Advanced Stage Cervical Cancer | 0.81 to 0.99 | 1.30* (0.77 to 1.84) | Advanced Stage SCC | 0.52 to 0.62 | 0.77* (0.11 to 1.42) | Advanced Stage Adeno carcinoma | 0.15 to 0.20 | 2.95* (2.30 to 3.60) |
| Age Group | | | Age Group | | | Age Group | | |
| 30–34 | 0.37 to 0.67 | 3.32* (2.01 to 4.64) | 30–34 | 0.26 to 0.43 | 2.81* (1.14 to 4.5) | 30–34 | | |
| 35–39 | 0.8 to 1.05 | 1.99* (0.91 to 3.08) | 35–39 | 0.61 to 0.65 | 1.33* (0.08 to 2.6) | 35–39 | | |
| 40–44 | 1.17 to 1.33 | 1.12 (–0.57 to 2.83) | 40–44 | 0.82 to 0.89 | 1.28 (–0.05 to 2.63) | 40–44 | | |
| 45–49 | 1.23 to 1.93 | 2.17* (1.27 to 3.08) | 45–49 | 0.87 to 1.26 | 1.42* (0.3 to 2.57) | 45–49 | | |
| 50–54 | 1.68 to 2.2 | 2.17* (1.4 to 2.94) | 50–54 | 1.22 to 1.5 | 2.04* (0.59 to 3.51) | 50–54 | 0.24 to 0.38 | 3.00* (1.66 to 4.35) |
| 55–59 | 1.71 to 2.3 | 1.29* (0.21 to 2.37) | 55–59 | 1.11 to 1.59 | 1.55* (0.84 to 2.25) | 55–59 | 0.24 to 0.37 | 3.75* (1.95 to 5.58) |
| 60–64 | 1.99 to 2.18 | 1.13 (–0.05 to 2.33) | 60–64 | 1.32 to 1.23 | 0.28 (–0.67 to 1.23) | 60–64 | 0.38 to 0.62 | 3.27* (1.58 to 4.99) |
| 65–69 | 2.4 to 2.27 | 0.51 (–0.22 to 1.23) | 65–69 | 1.24 to 1.13 | 0.02 (–1.09 to 1.14) | 65–69 | 0.51 to 0.67 | 2.00* (0.72 to 3.3) |
| 70–74 | 1.96 to 2.26 | 1.34 (–1.22 to 3.97) | 70–74 | 1.13 to 1.21 | 2.19 (–0.35 to 4.79) | 70–74 | 0.51 to 0.55 | 2.24* (0.92 to 3.59) |
| 75–79 | 1.68 to 2.03 | 1.77* (0.59 to 2.95) | 75–79 | 0.83 to 1.28 | 1.54 (–0.42 to 3.53) | 75–79 | | |
| 80+ | 2.04 to 1.88 | –0.08 (–1.15 to 1.01) | 80+ | 1.1 to 0.94 | 0.58 (–0.7 to 1.88) | 80+ | | |
| Race/Ethnicity | | | Race/Ethnicity | | | Race/Ethnicity | | |
| NHW | 0.68 to 0.92 | 1.69* (0.91 to 2.47) | NHW | 0.51 to 0.51 | 1.12* (0.06 to 2.19) | NHW | 0.13 to 0.18 | 3.35* (2.54 to 4.16) |

| | AAI | | 2001–2018 | | | AAI | | 2001–2018 | |
|-----------|--------------|-----------------------|--------------|---------------|-----------------------|--------------|---------------|----------------------|--|
| | 2001 to 2018 | AAPC (95% CI) | 2001 to 2018 | AAPC (95% CI) | | 2001 to 2018 | AAPC (95% CI) | | |
| NHB | 1.4 to 1.55 | 0.67* (0.03 to 1.32) | NHB | 0.53 to 0.6 | 0.98 (-0.4 to 2.39) | NHB | 0.21 to 0.29 | 1.71* (0.45 to 3) | |
| Hispanic | 1.22 to 1.01 | -0.08 (-2.25 to 2.13) | Hispanic | 0.52 to 0.73 | 1.3 (-0.09 to 2.71) | Hispanic | 0.22 to 0.23 | 0.02 (-4.54 to 4.79) | |
| NHAPI | 0.93 to 0.67 | 0.14 (-1.27 to 1.56) | NHAPI | 0.54 to 0.51 | 0.33 (-0.38 to 1.04) | NHAPI | | | |
| Region | | | Region | | | Region | | | |
| Northeast | 0.82 to 0.87 | 1.38* (0.59 to 2.18) | Northeast | 0.44 to 0.57 | 1.37* (0.54 to 2.2) | Northeast | 0.16 to 0.18 | 2.46* (1.34 to 3.6) | |
| Midwest | 0.79 to 0.93 | 1.15 (-0.07 to 2.39) | Midwest | 0.95 to 0.99 | 0.08 (-0.69 to 0.85) | Midwest | 0.14 to 0.18 | 3.14* (1.85 to 4.44) | |
| South | 0.8 to 1.17 | 2.12* (1.25 to 2.99) | South | 0.86 to 0.59 | -0.57 (-1.68 to 0.55) | South | 0.14 to 0.24 | 3.84* (2.92 to 4.76) | |
| West | 0.84 to 0.82 | 0.65 (-0.02 to 1.31) | West | 0.52 to 0.43 | 0.49 (-1.35 to 2.36) | West | 0.15 to 0.18 | 1.66* (0.64 to 2.69) | |

Blank spaces indicate no data available.
 AAPC is a summary measure of the trend over a pre-specified fixed interval.
 *Percentages may not total 100 because of rounding.
 AAI, age-adjusted incidence; AAPC, average annual percent change; NHAPI, Non-Hispanic Asians or Pacific Islander; NHB, Non-Hispanic Black; NHW, Non-Hispanic White; USCS, United States Cancer Statistics.

© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Int J Gynecol Cancer 2023;**33**:317–318. doi:10.1136/ijgc-2022-003728corr2

